(Total Views: 773)
Posted On: 12/21/2020 1:12:00 PM
Post# of 153986
Agree that generic therapies are better than treatments (antibodies) and vaccines that target certain viral epitopes that may vary over time.
However, I doubt the newest SARS2 variant in SE UK is going to be problematic. We already have the D614G variant that took over in February. Vaccines developed against the original Wuhan strain work fine against the newer, easier to spread D614G variant, and I imagine they will work fine against this new UK strain/variant. The good news is that the vaccines targeted the whole spike protein, so there will be multiple antibodies and memory cells against different parts of the spike protein. If there is a single AA change at one or even two or three locations, it is unlikely to escape the vaccine induced immunity. Right now the media is hyping and scaremongering, like they always do. The new variant hasn't been tested in the lab for infective efficiency yet so they kinda just pulled the 70% number out of a hat, it seems to me.
Can't wait to see what LL did in S/C trial. It will seem like a long wait.
However, I doubt the newest SARS2 variant in SE UK is going to be problematic. We already have the D614G variant that took over in February. Vaccines developed against the original Wuhan strain work fine against the newer, easier to spread D614G variant, and I imagine they will work fine against this new UK strain/variant. The good news is that the vaccines targeted the whole spike protein, so there will be multiple antibodies and memory cells against different parts of the spike protein. If there is a single AA change at one or even two or three locations, it is unlikely to escape the vaccine induced immunity. Right now the media is hyping and scaremongering, like they always do. The new variant hasn't been tested in the lab for infective efficiency yet so they kinda just pulled the 70% number out of a hat, it seems to me.
Can't wait to see what LL did in S/C trial. It will seem like a long wait.
(5)
(0)
